Deregulated degradation of the cdk inhibitor p27 and malignant transformation

Seminars in Cancer Biology

Volumn 13, Issue 1, 2003, Pages 41-47

  Bloom, Joanna ^a   Pagano, Michele ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Cell cycle; F box proteins; p27; Proteolysis; SCF ubiquitin ligases; Skp2; Ubiquitin

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEASOME; PROTEIN DERIVATIVE; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2; UNCLASSIFIED DRUG;

CARCINOGENESIS; CARCINOGENICITY; CELL CYCLE; HUMAN; NONHUMAN; PROTEIN DEGRADATION; REVIEW;

EID: 0037325853     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-579X(02)00098-6     Document Type: Article

References (72)

1. Morgan M. Principles of cdk regulation. Nature. 374:1995;131-134.
2. Sherr C., Roberts J. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
3. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1999;1501-1512.
4. Draetta G. Mammalian G1 cyclins. Curr. Opin. Cell. Biol. 6:1994;842-846.
5. Koff A., Ohtsuki M., Polyak K., Roberts J., Massague J. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-β Science. 260:1993;536-539.
6. kip1 , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 79:1994;59-66.
7. Hengst L., Dulic V., Slingerland J., Lees E., Reed S. A cell cycle regulated inhibitor of cyclin-dependent kinases. Proc. Natl. Acad. Sci. U.S.A. 91:1994;5291-5295.
8. Slingerland J., Hengst L., Pan C., Alexander D., Stampfer M., Reed S. A novel inhibitor of cyclin-Cdk activity detected in TGFβ-arrested epitehelial cells. Mol. Cell. Biol. 14:1994;3683-3694.
9. Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature. 382:1996;325-331.
10. De Bondt H.L., Rosenblatt J., Jancarik J., Jones H.D., Morgan D.O., Kim S.H. Crystal structure of human cdk2: implications for the regulation of cyclin-dependent kinases by phosphorylation and cyclin binding. Nature. 363:1993;595-602.
11. Morgan D. The dynamics of cyclin-dependent kinase structure. Curr. Opin. Cell. Biol. 8:1996;339-363.
12. Pagano M., Tam S., Theodoras A., Beer P., Delsal S., Chau I.et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 269:1995;682-685.
13. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67:1998;425-479.
14. Kip1 . Genes Dev. 11:1997;1464-1478.
15. Kip1 . EMBO J. 16:1997;5334-5344.
16. Montagnoli A., Fiore F., Eytan E., Carrano A.C., Draetta G., Hershko A.et al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev. 13:1999;1181-1189.
17. Nguyen H., Gitig D.M., Koff A. Cell-free degradation of p27(kip1), a G1 cyclin-dependent kinase inhibitor, is dependent on CDK2 activity and the proteasome. Mol. Cell. Biol. 19:1999;1190-1201.
18. Tomoda K., Kubota Y., Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27 is instigated by Jab1. Nature. 398:1999;160-164.
19. Rodier G., Montagnoli A., Di Marcotullio L., Coulombe P., Draetta G.F., Pagano M.et al. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J. 20:2001;6672-6682.
20. kip cytoplasmic translocation mediates cell motility independent of cell cycle arrest, submitted for publication.
21. Carrano A.C., Eytan E., Hershko A., Pagano M. Skp2 is required for the ubiquitin-mediated degradation of the Cdk-inhibitor p27. Nat. Cell. Biol. 1:1999;193-199.
22. Kip1 degradation and induces S phase in quiescent cells. Nat. Cell. Biol. 1:1999;207-214.
23. Skp2 complex through phosphorylated Thr187 in p27. Curr. Biol. 9:1999;661-664.
24. DeSalle L., Pagano M. Regulation of the G1/S transition by the ubiquitin pathway. FEBS Lett. 490:2001;1-11.
25. Skp2 -mediated ubiquitinylation of p27. Nat. Cell. Biol. 3:2001;321-324.
26. Skp2 to the CDK inhibitor p27. Mol. Cell. 7:2001;639-650.
27. Kip1 in G1 and S phase. Nature. 413:2001;323-327.
28. Hara T., Kamura T., Nakayama K., Oshikawa K., Hatakeyama S., Nakayama K. Degradation of p27(Kip1) at the G(0)-G(1) transition mediated by a Skp2-independent ubiquitination pathway. J. Biol. Chem. 276:2001;48937-48943.
29. Kip1 accumulation during the cell cycle. Science. 271:1996;1861-1864.
30. Kip1 -deficient mice. Cell. 85:1996;733-744.
31. Kip1 . Cell. 85:1996;721-732.
32. Nakayama K., Ishida N., Shirane M., Inomata A., Inoue T., Shishido N.I.H.et al. Mice lacking p27 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 85:1996;707-720.
33. Park M.S., Rosai J., Nguyen H.T., Capodieci P., Cordon-Cardo C., Koff A. p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc. Natl. Acad. Sci. U.S.A. 96:1999;6382-6387.
34. Kip1 is haplo-insufficient for tumour suppression. Nature. 396:1998;177-180.
35. Kip1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 27:2001;222-224.
36. Muraoka R.S., Lenferink A.E.G., Law B., Hamilton E., Brantley D.M., Roebuck L.R.et al. ErbB2/neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol. Cell. Biol. 22:2002;2204-2219.
37. Kip1 , polyploidy and centrosome overduplication. EMBO J. 19:2000;2069-2081.
38. Yoshida K., Nakayama K., Nagahama H., Harada T., Harada C., Imaki J.et al. Involvement of p27(KIP1) degradation by Skp2 in the regulation of proliferation in response to wounding of corneal epithelium. Invest. Ophthalmol. Vis. Sci. 43:2002;364-370.
39. Yu Z.K., Gervais J., Zhang H. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc. Natl. Acad. Sci. U.S.A. 95:1998;11324-11329.
40. Yam C.H., Ng R.W., Siu W.Y., Lau A.W., Poon R.Y. Regulation of cyclin A-Cdk2 by SCF component Skp1 and F-box protein Skp2. Mol. Cell. Biol. 19:1999;635-645.
41. Kawamata N., Morosetti R., Miller C.W., Park D., Spirin K.S., Nakamaki T.et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/kip1 in human malignancies. Cancer Res. 55:1995;2266-2269.
42. Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res. 55:1995;1206-1210.
43. Kip1 : chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res. 55:1995;1211-1214.
44. Spirin K.S., Simpson J.F., Takeuchi S., Kawamata N., Miller C.W., Koeffler H.P. p27/Kip1 mutation found in breast cancer. Cancer Res. 56:1996;2400-2404.
45. Dahia P.L., Aguiar R.C., Honegger J., Fahlbush R., Jordan S., Lowe D.G.et al. Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours. Oncogene. 16:1998;69-76.
46. Slingerland J., Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J. Cell. Physiol. 183:2000;10-17.
47. Esposito V., Baldi A., DeLuca A., Sgaramella G., Giordano G.G., Caputi M.et al. Prognostic role of the cell cycle inhibitor p27 in non small cell lung cancer. Cancer Res. 57:1997;3381-3385.
48. Loda M., Cukor B., Tam S., Lavin P., Fiorentino M., Draetta G.et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 3:1997;231-234.
49. Piva R., Cancelli I., Cavalla P., Bortolotto S., Dominguez J., Draetta G.F.et al. Proteasome-dependent degradation of p27/kip1 in gliomas. J. Neuropathol. Exp. Neurol. 58:1999;691-696.
50. Chiarle R., Budel L.M., Skolnik J., Frizzera G., Chilosi M., Corato A.et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood. 95:2000;619-626.
51. Kudo Y., Kitajima S., Sato S., Miyauchi M., Ogawa I., Takata T. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res. 61:2001;7044-7047.
52. Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. Am. J. Pathol. 153:1998;505-513.
53. Latres E., Chiarle R., Schulman B., Pellicer A., Inghirami G., Pagano M. Role of the F-box protein Skp2 in lymphomagenesis. Proc. Natl. Acad. Sci. U.S.A. 98:2001;2515-2520.
54. Gstaiger M., Jordan R., Lim M., Catzavelos C., Mestan J., Slingerland J.et al. Skp2 is oncogenic and overexpressed in human cancers. Proc. Natl. Acad. Sci. U.S.A. 98:2001;5043-5048.
55. Hershko D., Bornstein G., Ben-Izhak O., Carrano A., Pagano M., Krausz M.et al. Inverse relationship between levels of p27 and its ubiquitin ligase subunit Skp2 in colorectal cancers. Cancer. 91:2001;1745-1751.
56. Chiarle R., Yan P., Piva R., Boggino H., Skolnik J., Novero D.et al. Skp2 expression in mon-Hodgking lymphomas inversely correlates with p27 expression and defines cells in S-phase. Am. J. Pathol. 160:2002;1457-1466.
57. Signoretti S, DiMarcotullio L, Richardson A, Ramaswamy S, Rue M, Isaac B, et al. Molecular analysis and role of the F-box protein Skp2 in human breast cancer. J Clin Invest, in press.
58. Bartek J., Lukas J. p27 destruction: Cks1 pulls the trigger. Nat. Cell. Biol. 3:2001;E95-E98.
59. Gstaiger M., Jordan R., Lim M., Catzavelos C., Mestan J., Slingerland J.et al. Function of human Skp2 as an oncogene. Proc. Natl. Acad. Sci. U.S.A. 98:2001;5043-5048.
60. Nelsen C.J., Hansen L.K., Rickheim D.G., Chen C., Stanley M.W., Krek W.et al. Induction of hepatocyte proliferation and liver hyperplasia by the targeted expression of cyclin E and skp2. Oncogene. 20:2001;1825-1831.
61. Wirbelauer C., Sutterluty H., Blondel M., Gstaiger M., Peter M., Reymond F.et al. The F-box protein Skp2 is a ubiquitylation target of a Cul1-based core ubiquitin ligase complex: evidence for a role of Cul1 in the suppression of Skp2 expression in quiescent fibroblasts. EMBO J. 19:2000;5362-5375.
62. Carrano A.C., Pagano M. Role of the F-box protein Skp2 in adhesion-dependent cell cycle progression. J. Cell. Biol. 153:2001;1381-1389.
63. Kip1 in anchorage-independent cells. Oncogene. 16:1998;2575-2583.
64. Singh S.P., Lipman J., Goldman H., Ellis F.H. Jr., Aizenman L., Cangi M.G.et al. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res. 58:1998;1730-1735.
65. Kip1 in multistage colorectal carcinogenesis. Cancer Res. 58:1998;114-122.
66. Baldassarre G., Belletti B., Bruni P., Boccia A., Trapasso F., Pentimalli F.et al. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J. Clin. Invest. 104:1999;865-874.
67. Philipp-Staheli J., Payne S.R., Kemp C.J. p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp. Cell. Res. 264:2001;148-168.
68. Ishida N., Hara T., Kamura T., Yoshida M., Nakayama K., Nakayama K.I. Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J. Biol. Chem. 277:2002;14355-14358.
69. Yokoi S., Yasui K., Saito-Ohara F., Koshikawa K., Iizasa T., Fujisawa T.et al. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am. J. Pathol. 161:2002;207-216.
70. Masuda T.A., Inoue H., Sonoda H., Mine S., Yoshikawa Y., Nakayama K.et al. Clinical and biological significance of Skp2 gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res. 62:2002;3819-3825.
71. Boehm M., Yoshimoto T., Crook M.F., Nallamshetty S., True A., Nabel G.et al. A growth factor-dependent nuclear kinase phosphorylates p27(Kip1) and regulates cell cycle progression. EMBO J. 21:2002;3390-3401.
72. Fujita N., Sato S., Katayama K., Tsuruo T. Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem. 277:2002;28706-28713.